Biosense Webster

About

Biosense Webster develops solutions designed to diagnose and treat cardiac arrhythmias. The company enables physicians to find and treat more types of disease by contributing directly to improving procedural methodologies and raising success rates. Biosense Websters CARTO Solutions provide navigational and mapping features to help physicians better treat theirpatients. Advanced 3D mapping modules integrate multiple datasets and images into one resource for highly detailed, real-time information. The company is a division of Johnson & Johnson Medical NV/SA.

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

When was Biosense Webster acquired and by whom?

Biosense Webster was acquired by Johnson & Johnson in September 1997 for $427 million.

What is Biosense Webster's primary focus?

Biosense Webster develops solutions for the diagnosis and treatment of cardiac arrhythmias, including navigational and mapping features for physicians.

What is one of Biosense Webster's key product lines?

Biosense Webster's CARTO Solutions provide advanced 3D mapping modules that integrate multiple datasets and images for real-time information to assist physicians.

What was a significant product launch by Biosense Webster in October 2022?

In October 2022, Biosense Webster launched HELIOSTAR™ in Europe, which is a radiofrequency Balloon Ablation Catheter designed for more efficient cardiac ablations.

What mapping catheter did Biosense Webster launch in September 2022?

In September 2022, Biosense Webster launched the OCTARAY™ Mapping Catheter with TRUEref™ Technology.

What type of data network did Biosense Webster launch in May 2019?

In May 2019, Biosense Webster launched a cloud-based cardiac ablation data network.

What was the focus of a report launched by Biosense Webster in November 2018?

In November 2018, Biosense Webster launched a report titled 'The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe'.

What agreement did Biosense Webster extend with Stereotaxis in June 2018?

In June 2018, Biosense Webster and Stereotaxis extended their development alliance and supply agreement.

What product did Biosense Webster launch in May 2018 to improve ablation procedures?

In May 2018, Biosense Webster, Inc. launched a sheath designed to reduce radiation exposure and improve ablation procedure efficiency.

Sectors & technology

Primary sector

Health Tech & Life Sciences

Sub-sectors

Health Tech & Life SciencesMedical DevicesDiagnostics DevicesMedical Treatment & Therapeutics

Technologies

Simulation & ImagingUltrasound

Target customers

Healthcare & Life SciencesHealthcareProviders

Business model

B2CB2B

Biosense Webster — Full Company Profile (machine-readable)

Diagnosis and Treatment of Cardiac Arrhythmias

About

Facts

Name	Biosense Webster
Slug	biosense-webster
Type	Israeli Startup
Founded	1993
HQ city	Yokne'am Illit
HQ country	IL
Primary sector	[object Object]
Sectors	[object Object], [object Object], [object Object], [object Object]
Business models	B2C, B2B
Target customers	[object Object], [object Object], [object Object]
Status	acquired
Current stage	Acquired
Public stage	Acquired
Total raised (USD)	0
Website	http://www.biosensewebster.com
Crunchbase ID	biosense-webster
Israeli Companies Registrar	511859134

Acquisitions (1)

Date	Target	Amount	Type
1997-09	Undisclosed	$427,000,000

Team (2)

Name	Role	LinkedIn
Avi Shalgi
Eti Godelnik

News mentions (10)

Oct 17, 2022 — www.news-medical.net: Article
Sep 6, 2022 — www.jnj.com: Article
Jul 1, 2019 — www.medicaldesignandoutsourcing.com: Article
May 16, 2019 — www.fiercebiotech.com: Article
Nov 19, 2018 — www.businesswire.com: Article
Oct 1, 2018 — cardiacrhythmnews.com: Article
Jun 25, 2018 — globenewswire.com: Article
May 7, 2018 — www.prnewswire.com: Article
Jan 1, 2013 — www.globes.co.il: Article
Sep 29, 1997 — www.globes.co.il: Article

Intelligence Q&A

When was Biosense Webster acquired and by whom?

Biosense Webster was acquired by Johnson & Johnson in September 1997 for $427 million.

What is Biosense Webster's primary focus?

Biosense Webster develops solutions for the diagnosis and treatment of cardiac arrhythmias, including navigational and mapping features for physicians.

What is one of Biosense Webster's key product lines?

Biosense Webster's CARTO Solutions provide advanced 3D mapping modules that integrate multiple datasets and images for real-time information to assist physicians.

What was a significant product launch by Biosense Webster in October 2022?

In October 2022, Biosense Webster launched HELIOSTAR™ in Europe, which is a radiofrequency Balloon Ablation Catheter designed for more efficient cardiac ablations.

What mapping catheter did Biosense Webster launch in September 2022?

In September 2022, Biosense Webster launched the OCTARAY™ Mapping Catheter with TRUEref™ Technology.

What type of data network did Biosense Webster launch in May 2019?

In May 2019, Biosense Webster launched a cloud-based cardiac ablation data network.

What was the focus of a report launched by Biosense Webster in November 2018?

In November 2018, Biosense Webster launched a report titled 'The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe'.

What agreement did Biosense Webster extend with Stereotaxis in June 2018?

In June 2018, Biosense Webster and Stereotaxis extended their development alliance and supply agreement.

What product did Biosense Webster launch in May 2018 to improve ablation procedures?

In May 2018, Biosense Webster, Inc. launched a sheath designed to reduce radiation exposure and improve ablation procedure efficiency.

About

Company Intelligence Q&A

Sectors & technology

Highlights

Tags